CD38 and Miyoshi myopathy: Besides, the administration of CAR‐NKs showed effectiveness in the induction of apoptosis in CSCs of MM, as in an experiment on MM patients, the combination therapy of Daratumumab (anti‐CD38) and CAR‐NK‐cells targeting CS1, which is highly expressed in MM CSCs compared to any other cell type, demonstrated potential anti‐tumor effect and inhibited MM relapse through the elimination of MM stem cells.143